CRISPR Therapeutics Reports Positive Phase 1 Trial Results for Heart Disease Therapy

CRISPR Therapeutics has announced new results from a Phase 1 trial for CTX310, a gene editing therapy for high triglycerides and LDL cholesterol. The trial showed positive safety and efficacy data, with no serious adverse events reported. CRISPR plans to move forward with the trial and evaluate CTX310 in a larger patient population. The therapy aims to address cardiovascular disease by reducing levels of "bad" cholesterol.